LILA Jumps 51.5% as EPS Revisions Fuel 5-Stock Rally
Today's top performers were driven by earnings estimate revisions. LILA led with a 51.5% gain after its EPS growth estimate was raised from 208.4% to 340.3%. Other notable movers include LILAK (+49.9%), HELP (+45.0%), BDSX (+39.0%), and QNRX (+34.1%), all benefiting from upward EPS revisions.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| LILA | Communication Services | 2026-06-18 | +131.8pp | +51.5% |
| LILAK | Communication Services | 2026-06-18 | +1799.9pp | +49.9% |
| HELP | Healthcare | 2026-06-21 | N/A | +45.0% |
| BDSX | Healthcare | 2026-06-18 | +2.5pp | +39.0% |
| QNRX | Healthcare | 2026-06-23 | +9.5pp | +34.1% |
Why did LILA stock jump in June 2026?
LILA jumped 51.5% (from $4.80 to $7.27) after analysts raised its forward EPS growth estimate from 208.4% to 340.3% on June 18.
The 131.8 percentage point revision signaled a sharp turnaround in earnings expectations, driving strong buying pressure. The stock continued to rally as the market absorbed the improved outlook, with no additional news catalysts in the window. This move was part of a broader surge in Liberty Latin America shares, with sister company LILAK also posting large gains.
LILA EPS revision history → · Screener snapshot from 2026-06-18 →
FAQ: LILA
Why did LILA stock jump in June 2026?
LILA surged 51.5% after analysts raised its forward EPS growth estimate from 208.4% to 340.3% on June 18, reflecting a major improvement in expected earnings.
Is LILA a buy after the rally?
With the EPS revision implying a 340.3% growth rate next year, the stock may still have upside if earnings materialize, but investors should consider the 51.5% run-up and lack of news catalysts.
What is LILA's EPS growth estimate?
LILA's forward EPS growth estimate was revised from 208.4% to 340.3% on June 18.
Why did LILAK stock jump in June 2026?
LILAK jumped 49.9% (from $4.79 to $7.18) after analysts raised its forward EPS growth estimate from 413.6% to 2213.6% on June 18.
The extraordinary revision—an increase of nearly 1800 percentage points—reflected a dramatic expected earnings recovery. The stock surged in response, tracking its sister company LILA, with no other news in the window.
LILAK EPS revision history → · Screener snapshot from 2026-06-18 →
FAQ: LILAK
Why did LILAK stock jump in June 2026?
LILAK rose 49.9% after analysts revised its EPS growth estimate from 413.6% to 2213.6% on June 18, the largest revision among the group.
Is LILAK a buy after the rally?
The 2213.6% EPS growth estimate is extremely high; investors should evaluate the sustainability of such growth before buying after the 49.9% rally.
What caused LILAK's surge?
The surge was caused by an upward EPS revision of 1799.9 percentage points, signaling a massive expected improvement in earnings, with no other catalysts.
Why did HELP stock jump in June 2026?
HELP jumped 45.0% (from $4.67 to $6.77) after analysts revised its forward EPS growth estimate upward, reaching 27.7% for next year, on June 21.
The revision was reinforced by Helus Pharma's fiscal 2026 results on June 29, which highlighted strong institutional backing and positive Phase 3 trial enrollment for its MDD drug HLP003, with topline data expected Q4 2026. The stock surged as investors priced in the improved earnings trajectory and clinical progress.
HELP EPS revision history → · Screener snapshot from 2026-06-21 →
FAQ: HELP
Why did HELP stock jump in June 2026?
HELP rose 45.0% after analysts raised its EPS growth estimate to 27.7% on June 21, coupled with positive fiscal 2026 results and Phase 3 trial updates on June 29.
Is HELP a buy after the rally?
With a 27.7% EPS growth estimate and promising clinical data, HELP may have further upside, but the 45% rally already prices in much of the good news.
What is HELP's EPS growth estimate?
HELP's forward EPS growth estimate currently stands at 27.7% for next year.
Why did BDSX stock jump in June 2026?
BDSX jumped 39.0% (from $16.81 to $23.37) after analysts raised its forward EPS growth estimate from 38.2% to 40.7% on June 18.
The modest 2.5 percentage point revision nonetheless signaled improving earnings expectations for Biodesix, a healthcare diagnostics company. The market responded positively, pushing the stock higher amid sector-wide momentum in healthcare.
BDSX EPS revision history → · Screener snapshot from 2026-06-18 →
FAQ: BDSX
Why did BDSX stock jump in June 2026?
BDSX gained 39.0% after analysts raised its EPS growth estimate from 38.2% to 40.7% on June 18, confirming an improving earnings outlook.
Is BDSX a buy after the rally?
The 2.5 percentage point revision is small, but the 39% price jump suggests strong momentum; investors should monitor whether earnings growth actually accelerates.
What is BDSX's EPS growth estimate?
BDSX's forward EPS growth estimate was revised to 40.7% on June 18.
Why did QNRX stock jump in June 2026?
QNRX jumped 34.1% (from $3.25 to $4.36) after analysts raised its forward EPS growth estimate from 45.4% to 54.8% on June 23.
The 9.5 percentage point upward revision indicated a strengthening earnings outlook for Quoin Pharmaceuticals, likely driven by pipeline progress. The stock rallied as the market priced in the improved estimates, with no additional news in the window.
QNRX EPS revision history → · Screener snapshot from 2026-06-23 →
FAQ: QNRX
Why did QNRX stock jump in June 2026?
QNRX rose 34.1% after analysts raised its EPS growth estimate from 45.4% to 54.8% on June 23, signaling stronger expected earnings.
Is QNRX a buy after the rally?
With a 54.8% EPS growth estimate and no negative catalysts, QNRX may have room to run, but the 34% rally already reflects the revision.
What is QNRX's EPS growth estimate?
QNRX's forward EPS growth estimate was revised to 54.8% on June 23.
Today's gains underscore strong investor appetite for companies with improving earnings trajectories, particularly in Communication Services and Healthcare sectors. The market is rewarding even modest revisions with significant price appreciation, signaling a bullish sentiment on forward earnings.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →